Preliminary report of a phase I/II trial to assess safety and tolerability of an oral Aurora kinase A inhibitor, MLN 8237 (alisertib), in combination with erlotinib in patients with recurrent or metastatic non-small cell lung cancer (NSCLC).

被引：0
|
作者：
Borghaei, Hossein [1 ]
Mehra, Ranee [1 ]
Litwin, Samuel [1 ]
Astsaturov, Igor [1 ]
机构：
[1] Fox Chase Canc Ctr, Philadelphia, PA 19111 USA
来源：
CANCER RESEARCH | 2013年 / 73卷 / 08期
关键词：
D O I：
10.1158/1538-7445.AM2013-LB-170
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
LB170
引用
收藏
页数：1
相关论文
共 50 条
  • [1] A phase I/II study of MLN-8237 (alisertib), an oral aurora kinase inhibitor, in combination with erlotinib in patients with recurrent or metastatic EGFR wild-type non-small cell lung cancer.
    Godwin, James Luke
    Mehra, Ranee
    Litwin, Samuel
    Olszanski, Anthony J.
    Bauman, Jessica Ruth
    Borghaei, Hossein
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [2] A Phase I/II Study of Alisertib, an Oral Aurora Kinase Inhibitor, in Combination with Erlotinib in Patients with Recurrent or Metastatic NSCLC
    Godwin, James
    Bauman, Jessica
    Litwin, Samuel
    Mehra, Ranee
    Olszanski, Anthony
    Borghaei, Hossein
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S898 - S899
  • [3] Phase I trial evaluating the epidermal growth factor receptor inhibitor erlotinib in combination with the SRC kinase inhibitor dasatinib for patients with recurrent non-small cell lung cancer (NSCLC)
    Chiappori, A. A.
    Tanvetyanon, T.
    Williams, C. A.
    Antonia, S.
    Litschauer, S.
    Neuger, A.
    Lush, R.
    Haura, E. B.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [4] Phase I/II study of the investigational aurora A kinase (AAK) inhibitor MLN8237 (alisertib) in patients (pts) with non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), breast cancer (BrC), head/neck cancer (H&N), and gastroesophageal (GE) adenocarcinoma: Preliminary phase II results.
    Lee, Peter
    Alvarez, Ricardo H.
    Melichar, Bohuslav
    Adenis, Antoine
    Bennouna, Jaafar
    Schusterbauer, Claudia
    Zhang, Bin
    Benaim, Ely
    Rosen, Peter J.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [5] MLN8237 (ALISERTIB), A SELECTIVE AURORA A KINASE (AAK) INHIBITOR, IN PATIENTS WITH RELAPSED/REFRACTORY SMALL CELL LUNG CANCER (SCLC): PHASE 2 RESULTS
    Havel, Libor
    Dees, Claire
    Lockhart, Craig
    Bennouna, Jaafar
    Serwatowski, Piotr
    Liu, Stephen
    Niu, Huifeng
    Badola, Sunita
    Schusterbauer, Claudia
    Ullmann, Claudio Dansky
    Zhang, Bin
    Benaim, Ely
    JOURNAL OF THORACIC ONCOLOGY, 2013, 8 : S221 - S222
  • [6] A PHASE I / II TRIAL OF THE HDAC INHIBITOR BELINOSTAT IN COMBINATION WITH ERLOTINIB IN PATIENTS WITH NON-SMALL CELL LUNG CANCER.
    Andersen, Jon L.
    Holm, Bente
    Rasmussen, Trine S.
    Mellemgaard, Anders
    JOURNAL OF THORACIC ONCOLOGY, 2013, 8 : S1201 - S1202
  • [7] A phase I/II trial of MM-121 in combination with erlotinib in patients (pts) with non-small cell lung cancer (NSCLC).
    Sequist, L. V.
    Harb, W. A.
    Modiano, M.
    Jackman, D. M.
    Wong, K.
    Engelman, J. A.
    Nering, R.
    Onsum, M.
    Moyo, V. M.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [8] A phase II trial of the aurora kinase A inhibitor MLN8237 in patients with metastatic castrate resistant and neuroendocrine prostate cancer.
    Beltran, Himisha
    Rubin, Mark A.
    Mosquera, Juan Miguel
    Christos, Paul J.
    Calukovic, Olivera
    Karpenko, Irene
    Pinski, Jacek K.
    Danila, Daniel Costin
    Nanus, David M.
    Tagawa, Scott T.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [9] Erlotinib in combination with bevacizumab for patients with recurrent non-small-cell lung cancer: a phase I/II trial
    Herbst, Roy S.
    Johnson, David
    Blumenschein, George
    Henderson, Ted
    Liu, Diane
    Truong, Mylene
    Ramies, David
    Mass, Robert
    Garcia, Ben
    Sandler, Alan B.
    ANNALS OF ONCOLOGY, 2004, 15 : 170 - 170
  • [10] MLN8237 (ALISERTIB), AN INVESTIGATIONAL AURORA A KINASE INHIBITOR, IN PATIENTS (PTS) WITH NON-SMALL CELL LUNG CANCER (NSCLC), SMALL CELL LUNG CANCER (SCLC), BREAST CANCER (BRC), HEAD AND NECK SQUAMOUS CELL CARCINOMA (HNSCC), AND GASTROESOPHAGEAL CANCER (GE): EMERGING PHASE (PH) 2 RESULTS
    Melichar, B.
    Lee, P.
    Alvarez, R. H.
    Degardin, M.
    Bennouna, J.
    Schusterbauer, C.
    Zhang, B.
    Benaim, E.
    Rosen, P.
    ANNALS OF ONCOLOGY, 2012, 23 : 160 - 160
12345